TEVA PE Ratio & Valuation, Is TEVA Overvalued

Historical Valuation

Teva Pharmaceutical Industries Limited.. (TEVA) is now in the Overvalued zone, suggesting that its current forward PE ratio of 13.33 is considered Overvalued compared with the five-year average of 5.10. The fair price of Teva Pharmaceutical Industries Limited.. (TEVA) is between 14.37 to 23.91 according to relative valuation method. Compared to the current price of 35.73 USD , Teva Pharmaceutical Industries Limited.. By Overvalued By 49.44%.

Relative Value

Fair Zone

14.37-23.91

Current Price：35.73

49.44%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Teva Pharmaceutical Industries Limited.. (TEVA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Teva Pharmaceutical Industries Limited.. (TEVA) has a current Price-to-Book (P/B) ratio of 5.10. Compared to its 3-year average P/B ratio of 2.88, the current P/B ratio is approximately 76.68% higher. Relative to its 5-year average P/B ratio of 2.16, the current P/B ratio is about 136.40% higher. Teva Pharmaceutical Industries Limited.. (TEVA) has a Forward Free Cash Flow (FCF) yield of approximately 2.80%. Compared to its 3-year average FCF yield of 5.26%, the current FCF yield is approximately -46.86% lower. Relative to its 5-year average FCF yield of 4.74%, the current FCF yield is about -41.05% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TEVA competitors is 2.42, providing a benchmark for relative valuation. Teva Pharmaceutical Industries Limited.. Corp (TEVA.N) exhibits a P/S ratio of 2.42, which is 0% above the industry average. Given its robust revenue growth of 1.33%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TEVA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TEVA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TEVA currently overvalued or undervalued?

Teva Pharmaceutical Industries Limited.. (TEVA) is now in the Overvalued zone, suggesting that its current forward PE ratio of 13.33 is considered Overvalued compared with the five-year average of 5.10. The fair price of Teva Pharmaceutical Industries Limited.. (TEVA) is between 14.37 to 23.91 according to relative valuation method. Compared to the current price of 35.73 USD, Teva Pharmaceutical Industries Limited.. is Overvalued By 49.44%.

What is Teva Pharmaceutical Industries Limited.. (TEVA) fair value?

TEVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Teva Pharmaceutical Industries Limited.. (TEVA) is between 14.37 to 23.91 according to relative valuation method.

How does TEVA's valuation metrics compare to the industry average?

The average P/S ratio for TEVA's competitors is 2.42, providing a benchmark for relative valuation. Teva Pharmaceutical Industries Limited.. Corp (TEVA) exhibits a P/S ratio of 2.42, which is 0.00% above the industry average. Given its robust revenue growth of 1.33%, this premium appears unsustainable.

What is the current P/B ratio for Teva Pharmaceutical Industries Limited.. (TEVA) as of May 11 2026?

As of May 11 2026, Teva Pharmaceutical Industries Limited.. (TEVA) has a P/B ratio of 5.10. This indicates that the market values TEVA at 5.10 times its book value.

What is the current FCF Yield for Teva Pharmaceutical Industries Limited.. (TEVA) as of May 11 2026?

As of May 11 2026, Teva Pharmaceutical Industries Limited.. (TEVA) has a FCF Yield of 2.80%. This means that for every dollar of Teva Pharmaceutical Industries Limited..'s market capitalization, the company generates 2.80 cents in free cash flow.

What is the current Forward P/E ratio for Teva Pharmaceutical Industries Limited.. (TEVA) as of May 11 2026?

As of May 11 2026, Teva Pharmaceutical Industries Limited.. (TEVA) has a Forward P/E ratio of 13.33. This means the market is willing to pay $13.33 for every dollar of Teva Pharmaceutical Industries Limited..'s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Teva Pharmaceutical Industries Limited.. (TEVA) as of May 11 2026?

As of May 11 2026, Teva Pharmaceutical Industries Limited.. (TEVA) has a Forward P/S ratio of 2.42. This means the market is valuing TEVA at $2.42 for every dollar of expected revenue over the next 12 months.

TEVA Valuation